This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...
In acute myeloid leukemia (AML) that is in complete remission, minimal residual disease (MRD) is presumed to be present, though not morphologically evident. Advances in diagnostics now permit the ...
SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...
OGT, using their specialised expertise in the development of superior hybridisation-based capture technology, ensures that ...
AML often responds well to initial treatment, but residual cancer cells frequently cause relapse. Break Through Cancer’s Eradicating Minimal Residual Disease in AML TeamLab aims to accelerate cures by ...
Ten AML patients dosed across 40 mg, 80 mg, and 120 mg TUS with TUS+VEN+AZA triplet SAN DIEGO and TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: ...
Management reiterated plans to initiate two Phase 3 trials under the KOMET-017 protocol for frontline AML in the second half of 2025. The trials will use MRD-negative CR and CR as primary endpoints ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the full list of presentations by leading researchers ...
Detailed price information for Cullinan Therapeutics Inc (CGEM-Q) from The Globe and Mail including charting and trades.
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML Four received the 40 mg dose of TUS, three received the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback